A cell becomes cancerous when it accumulates genetic changes that override the normal controls on growth, division, and death. This doesn’t happen all at once. Research on lung and colon cancers suggests that as few as three key mutations, acquired sequentially over years or decades, can be enough to transform a normal cell into a lethal tumor. Some blood cancers may require only a single genetic event. The process is gradual, which is why cancer risk rises sharply with age.
Growth Signals That Won’t Turn Off
Normal cells contain genes called proto-oncogenes that promote healthy growth and division. They’re essential for things like wound healing and tissue renewal. But when one of these genes is altered by mutation or gets duplicated too many times, it can become permanently “on,” flooding the cell with signals to keep dividing regardless of whether new cells are needed. This mutated version is called an oncogene, and it acts like a stuck accelerator pedal. The cell no longer waits for external signals telling it to grow. It just grows.
Broken Brakes on Cell Division
If oncogenes are the accelerator, tumor suppressor genes are the brakes. These genes normally slow cell division, trigger DNA repair, or tell damaged cells to self-destruct. When tumor suppressor genes stop working, the cell loses its ability to pause and fix problems. Both copies of a tumor suppressor gene typically need to be knocked out before this protection fails, which is one reason cancer takes time to develop.
The most well-known tumor suppressor is p53, which is inactivated in roughly 50% of all human cancers. In a healthy cell, p53 can halt the cell cycle when DNA damage is detected or, if the damage is too severe, trigger the cell’s death. When p53 is lost, damaged cells survive and continue dividing, passing their errors on to future generations of cells.
How Quality Control Fails
Cells go through a carefully ordered sequence of steps when they divide, with built-in checkpoints that act like quality inspections. The most important checkpoint sits at the boundary between the cell’s growth phase and the phase where it copies its DNA. This is where the majority of cancer-related defects occur. If the proteins running this checkpoint are mutated, a cell with damaged DNA gets waved through instead of being stopped for repairs.
A second checkpoint catches problems just before the cell physically splits in two. Failures here can lead to cells with the wrong number of chromosomes, a condition called aneuploidy that further destabilizes the genome and accelerates the accumulation of additional mutations. Each failed checkpoint makes the next mutation more likely, creating a snowball effect.
Dodging Programmed Cell Death
Healthy cells have a built-in self-destruct program called apoptosis. When a cell detects that something has gone seriously wrong with its DNA or internal machinery, it kills itself to protect the body. Cancer cells find ways to disable this system.
One common strategy involves overproducing survival proteins that block the self-destruct signals. In many human tumors, these anti-death proteins are expressed at abnormally high levels, tipping the balance so the cell ignores every internal alarm telling it to die. The cell survives when it shouldn’t, and its descendants inherit the same refusal to self-destruct. Evading apoptosis is considered fundamental to cancer development, not just a side effect of it.
Achieving Immortality
Normal human cells can only divide a limited number of times. Each division shortens the protective caps on the ends of chromosomes, called telomeres, until they become too short for the cell to divide safely. At that point, the cell enters a state of permanent retirement called senescence.
Cancer cells bypass this limit. They reactivate an enzyme called telomerase, which rebuilds the chromosome caps after each division. Telomerase is silent in the vast majority of normal human tissues, active only in a handful of specialized cell types like certain stem cells and sperm-producing cells. Cancer cells are almost universally telomerase-expressing. This single change gives them the ability to divide indefinitely, which is why cancer cells cultured in a lab can keep growing for decades while normal cells cannot.
Building a Blood Supply
A growing tumor quickly outstrips the oxygen and nutrients available from nearby blood vessels. To solve this, cancer cells release signaling molecules that stimulate the growth of new blood vessels from existing ones, a process called angiogenesis. The primary signal involved is a protein released by cancer cells when they sense low oxygen levels. This protein binds to receptors on nearby blood vessel cells, triggering them to multiply and migrate toward the tumor.
The new blood vessels are typically disorganized and leaky compared to normal vasculature, but they’re sufficient to feed the tumor’s growth. Without this ability to recruit a blood supply, tumors generally can’t grow beyond a few millimeters in diameter.
Spreading to Other Tissues
The ability to invade surrounding tissue and spread to distant organs is what makes cancer deadly, and it requires yet another set of changes. Cancer cells can undergo a transformation where they lose the sticky connections that hold them in place among their neighbors and gain the ability to crawl through tissue. They essentially shift from a stationary, tightly packed cell type to a mobile, more loosely organized one.
This shift gives cancer cells migratory and invasive properties, allowing them to break through tissue boundaries, enter the bloodstream, and travel to distant sites. Once they arrive at a new organ, surviving cells reverse the process, reverting to a more stationary state that lets them anchor and colonize. This reversal appears to be critical for establishing new tumors at distant sites. The whole process is why a cancer that starts in, say, the colon can eventually appear in the liver or lungs.
Not All Changes Are Mutations
Cancer doesn’t always require direct damage to the DNA sequence itself. Cells can also be pushed toward cancer by epigenetic changes, which alter how genes are read without changing the underlying genetic code. The most studied mechanism involves chemical tags (methyl groups) being added to DNA near the start of a gene, which effectively silences it. If the silenced gene happens to be a tumor suppressor, the effect is the same as if the gene had been deleted: the cell loses a layer of protection against uncontrolled growth.
These epigenetic changes can also modify the proteins that DNA wraps around, further tightening or loosening access to specific genes. Unlike mutations, epigenetic changes are potentially reversible, which is one reason they’ve become a focus of cancer treatment research.
Inherited Risk vs. Acquired Damage
Up to 10% of all cancers may be caused by inherited genetic changes, meaning someone is born with one of the key mutations already present in every cell. This gives cancer a head start, since fewer additional mutations are needed to complete the transformation. Inherited mutations in well-known genes like BRCA1 and BRCA2 work this way, raising the risk of breast and ovarian cancers.
The vast majority of cancers, however, arise from mutations acquired during a person’s lifetime. These somatic mutations accumulate from a combination of normal errors during cell division, environmental exposures like ultraviolet radiation and tobacco smoke, and chronic inflammation. Because these mutations pile up over time, age is the single strongest risk factor for most cancers. Every cell division is a roll of the dice, and over decades, the odds of hitting the wrong combination increase substantially.
Why It Takes Multiple Hits
No single change is usually enough. A cell that gains an oncogene but still has working tumor suppressors will likely be held in check. A cell that loses p53 but doesn’t have an activated growth signal may survive longer than it should but won’t necessarily form a tumor. Cancer requires a convergence of failures: growth signals stuck on, brakes disabled, self-destruct programs silenced, and the ability to feed and spread. Research on lung and colon adenocarcinomas estimates that three sequential driver mutations are sufficient, though additional mutations commonly accumulate afterward, often varying from cell to cell within the same tumor. This internal diversity is part of what makes advanced cancers so difficult to treat, since different cells within a single tumor may respond differently to therapy.